Brookline Capital Markets Predicts INTS FY2030 Earnings

Intensity Therapeutics Inc. (NASDAQ:INTS) – Stock analysts at Brookline Capital Markets issued their FY2030 EPS estimates for shares of Intensity Therapeutics in a research report issued to clients and investors on Tuesday, April 14th. Brookline Capital Markets analyst K. Raja expects that the company will post earnings per share of $12.94 for the year. The consensus estimate for Intensity Therapeutics’ current full-year earnings is ($1.18) per share.

Intensity Therapeutics (NASDAQ:INTS) last announced its quarterly earnings results on Friday, March 27th. The company reported ($0.31) EPS for the quarter.

Several other brokerages also recently commented on INTS. Freedom Capital raised shares of Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Monday, December 22nd. Finally, Wall Street Zen upgraded shares of Intensity Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $37.50.

Intensity Therapeutics Stock Down 1.8%

Shares of NASDAQ:INTS opened at $5.36 on Wednesday. The firm has a fifty day moving average price of $6.82 and a two-hundred day moving average price of $8.89. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.92 and a quick ratio of 5.92. Intensity Therapeutics has a one year low of $4.63 and a one year high of $50.00. The company has a market cap of $13.61 million, a price-to-earnings ratio of -0.34 and a beta of 3.65.

Institutional Trading of Intensity Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its stake in Intensity Therapeutics by 77.8% in the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock worth $189,000 after purchasing an additional 201,357 shares during the last quarter. Mesirow Financial Investment Management Inc. lifted its stake in Intensity Therapeutics by 25.5% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock worth $103,000 after purchasing an additional 51,000 shares during the last quarter. Legacy Advisors LLC bought a new stake in Intensity Therapeutics in the fourth quarter worth $63,000. State Street Corp lifted its stake in Intensity Therapeutics by 839.3% in the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after purchasing an additional 121,700 shares during the last quarter. Finally, Corient Private Wealth LLC bought a new stake in Intensity Therapeutics in the fourth quarter worth $41,000. 3.74% of the stock is owned by institutional investors.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.